Document is current
Any future updates will be listed below
-
Authors
Kügler, Cosima
Witt, Stefanie
Hammersen, Johanna
Quitmann, Julia
Schneider, Holm https://orcid.org/0000-0002-8548-4053
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 13 April 2025
Accepted: 28 January 2026
First Online: 6 February 2026
Declarations
:
: This study was approved by the Ethics Committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg (reference number 21-412-B) and conducted in accordance with the principles of the declaration of Helsinki. All individuals and/or their legal guardians provided written informed consent to participate.
: Not applicable.
: Holm Schneider received both public and private funding for the current EDELIFE trial and holds a patent related to the prenatal therapy of XLHED, but signed a Remuneration Waiver Agreement to relinquish any personal financial gain from this invention; he has had a consulting or advisory role, received honoraria, research grants, and/or travel support from Edimer Pharmaceuticals, Krystal Biotech, Novartis, Pierre Fabre, Roche, SRE GmbH, and Wyeth Pharma GmbH.
